Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MRC Technology

- PMLiVE

AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster

Vaxzevria is a ‘viral vector’ vaccine, a technology that is also used to create vaccines for other infectious diseases like flu, HIV and Ebola

- PMLiVE

AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement

RQ BIO has developed a portfolio of early-stage monoclonal antibodies targeting SARS-CoV-2

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

- PMLiVE

Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients

Results of MANDALA trial will be presented at the American Thoracic Society (ATS) 2022 International Conference

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US

The drug combination offers biliary tract cancer patients a new treatment option

- PMLiVE

AstraZeneca unveils plans for new US R&D centre

The site, scheduled for completion in 2026, will also include the headquarters of Alexion

Connecting Diverse Communities to Elevate Healthcare

Dvorah Richler, Head of Soaring with Roche, and Michael Duong, Head of Innovation at Michael Duong, discuss the 5 healthcare challenges that Soaring with Roche aims to solve through innovative...

Impetus Digital

- PMLiVE

New study highlights significance of chronic obstructive pulmonary disease flare-ups

COPD causes nearly 30,000 deaths in England each year, with an annual overall cost to the NHS of £1.9bn

- PMLiVE

AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19

The drug decreases the risk of developing symptomatic COVID-19 by 77% among high-risk populations

- PMLiVE

Enhertu to provide patients with vital targeted therapy option

Therapy receives FDA priority review as patients with HER2-mutant metastatic non-small cell lung cancer seek alternative treatment

- PMLiVE

Sanofi’s asthma treatment approved by European Commission

Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation

- PMLiVE

AstraZeneca to present new oncology data at AACR

The American Association for Cancer Research Annual Meeting takes place in New Orleans from 8-13 April 2022

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links